Zinc Chloride
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Zinc Chloride: From No Approved Indication to Dry Eye Syndrome
One-Sentence Summary
Zinc Chloride (DB14533) has no approved indication in Taiwan and is not currently marketed there. The TxGNN model predicts it may be effective for Dry Eye Syndrome, with 2 clinical trials and no peer-reviewed literature currently supporting this direction — and none of the trials tested pure zinc chloride alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indications on record) |
| Predicted New Indication | Dry Eye Syndrome |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L2 |
| US/Taiwan Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Zinc Chloride. Based on known information, zinc is an essential trace element involved in mucin production, corneal epithelial integrity, and antioxidant defense at the ocular surface — biological roles that make an ophthalmic application mechanistically plausible.
Zinc-containing ophthalmic formulations (e.g., zinc-hyaluronate) have been tested in dry eye clinical trials, lending some real-world support to this direction. However, the existing evidence involves zinc combined with hyaluronic acid, or a formulation (PRO-148) whose zinc content is not clearly documented — not zinc chloride as a standalone active ingredient. As a result, the mechanistic plausibility is reasonable, but direct attribution of efficacy to zinc chloride itself cannot be confirmed from current data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02951910 | Phase 4 | Completed | 20 | Tested zinc-hyaluronate complex (formed by adding zinc chloride to sodium hyaluronate) as a mechanical/biocompatible barrier on the ocular surface to relieve dry eye symptoms; small sample (n=20), complex formulation — effect not isolated to zinc alone |
| NCT01541891 | Phase 2 | Completed | 30 | Compared PRO-148 ophthalmic solution vs. Systane for mild-to-moderate dry eye syndrome; PRO-148’s zinc content is not confirmed in available data, small sample (n=30), relevance uncertain |
Literature Evidence
Currently no related literature available.
US Market Information
No Taiwan/US market authorizations on record — Zinc Chloride is not currently marketed (0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA labeling/warnings data (DG001) and mechanism of action data (DG002) are currently unavailable and are blocking a full safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The only clinical evidence available involves zinc combined with other agents (hyaluronic acid) or formulations with undocumented zinc content, not zinc chloride alone. Combined with the absence of MOA data, TFDA labeling, and any published literature, the evidence is insufficient to move beyond a research question stage.
To proceed, the following is needed:
- TFDA/manufacturer labeling data (warnings, contraindications) — currently blocking
- Confirmed mechanism of action data for zinc chloride specifically
- Clinical or preclinical evidence isolating zinc chloride’s effect from combination formulations
- Peer-reviewed literature supporting the mucin/corneal epithelium mechanistic rationale in dry eye syndrome
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.